spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  familial hypercholesterolemia 

 HSMN NewsFeed - 12 Aug 2020
FDA Accepts Evinacumab Biologics License Application for Priority Review as a Treatment for Patients with HoFH, an Ultra-rare Inherited Form of High Cholesterol
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 18 May 2020
Akcea Announces Appointment of New Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Oct 2019
Amgen To Make Repatha(R) (evolocumab) Available Exclusively At Its Lower List Price Option In 2020
Biopharmaceuticals Cardiology Reimbursement
 HSMN NewsFeed - 14 Aug 2019
Regeneron Announces Positive Topline Results from Phase 3 Trial of Evinacumab in Patients with Severe, Inherited Form of High Cholesterol
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 31 Jul 2019
Results of the Pivotal Phase 3 Study of the Bempedoic Acid / Ezetimibe Combination Tablet Published in the European Journal of Preventative Cardiology Demonstrated Significant LDL-C Lowering
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 4 Feb 2019
CHMP Recommends Approval of Praluent(R) (alirocumab) Injection to Reduce Cardiovascular Risk in People with Established Atherosclerotic Cardiovascular Disease
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 12 Sep 2018
FDA to Review Supplemental Biologics License Application for Praluent(R) (alirocumab)Injection as Potential Treatment to Reduce Major Adverse Cardiovascular Events
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 1 May 2018
Regeneron and Sanofi to Lower Net Price of Praluent(R) (alirocumab) Injection in Exchange for Straightforward, More Affordable Patient Access for Express Scripts Patients
Biopharmaceuticals Reimbursement
 HSMN NewsFeed - 23 Mar 2018
Amgen Receives Positive CHMP Opinion Recognizing That Repatha(R) (evolocumab) Prevents Heart Attacks And Strokes
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 25 Aug 2017
Regeneron and Sanofi to Present New Analyses from Praluent(R) (alirocumab) Injection Trials at the ESC Congress 2017
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 28 Jul 2017
FDA Grants Priority Review For Amgen's Supplemental Biologics License Application For Repatha(R) (evolocumab) To Include Data On Reducing Risk Of Cardiovascular Events
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 25 Apr 2017
Sanofi and Regeneron Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent(R) (alirocumab) Injection
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 20 Mar 2017
Landmark Outcomes Study Shows that Repatha(R) (evolocumab) Decreases LDL-C to Unprecedented Low Levels and Reduces Risk of Cardiovascular Events with No New Safety Issues
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 22 Feb 2017
Repatha(R) (Evolocumab) Receives European Commission Approval For New 420 mg Single-Dose Delivery Option
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 9 Feb 2017
Appeals Court Grants Stay of Permanent Injunction for Praluent(R) (alirocumab) During Appeals Process
Biopharmaceuticals Cardiology Litigation
 HSMN NewsFeed - 3 Feb 2017
Amgen Announces Repatha(R) (Evolocumab) Significantly Reduced The Risk Of Cardiovascular Events In FOURIER Outcomes Study
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 9 Jan 2017
The Medicines Company Announces Positive Top-Line Results from Day 180 Interim Analysis in Ongoing ORION-1 Phase 2 Study of Inclisiran (formerly, PCSK9si)
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 6 Jan 2017
Regeneron and Sanofi to Appeal U.S. District Court Rulings in Ongoing Patent Litigation Regarding Praluent(R) (alirocumab) Injection
Biopharmaceuticals Cardiology Litigation
 HSMN NewsFeed - 5 Dec 2016
Novelion Therapeutics Subsidiary, Aegerion Pharmaceuticals, Enters Into Licensing Agreement With Amryt Pharma for LOJUXTA(R) (lomitapide)
Biopharmaceuticals Cardiology Licensing
 HSMN NewsFeed - 29 Nov 2016
Albireo Expands Team, Appoints Martha J. Carter as Chief Regulatory Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Nov 2016
Regeneron and Sanofi Announce Praluent(R) (alirocumab) Cardiovascular Outcomes Trial Will Continue as Planned Following Interim Analysis
Biopharmaceuticals
 HSMN NewsFeed - 8 Nov 2016
The Medicines Company Discontinues Development of MDCO-216, its Investigational Cholesterol Efflux Promoter
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 29 Aug 2016
Regeneron and Sanofi Present Positive Phase 3 Investigational Data for Praluent(R) (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 29 Aug 2016
New Repatha(R) (evolocumab) Analyses Show Efficacy and Safety Across Risk Groups in Results Presented at ESC Congress 2016
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 11 Aug 2016
Richard S. Levy, M. D., Appointed to Madrigal Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Jul 2016
Regeneron and Sanofi Announce Approval of Praluent(R) (alirocumab) for the Treatment of Hypercholesterolemia in Japan
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 14 Apr 2016
Synta and Madrigal Announce Merger Agreement to Create Leading Cardiovascular-Metabolic Diseases and NASH Company
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 4 Feb 2016
Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-3 Trial Of Repatha(R) (Evolocumab) In Statin-Intolerant Patients With High Cholesterol
Biopharmaceuticals
 HSMN NewsFeed - 22 Jan 2016
Amgen's Repatha(R) (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 28 Sep 2015
Regeneron and Sanofi Announce Approval of Praluent(R) (alirocumab) for the Treatment of Hypercholesterolemia in the European Union
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 16 Sep 2015
Amgen To Acquire Privately-Held Dezima Pharma
Biopharmaceuticals Cardiology Mergers & Acquisitions
 HSMN NewsFeed - 11 Sep 2015
Amgen Submits Application To FDA For New Delivery Option For Monthly Administration Of Repatha(TM) (Evolocumab)
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 24 Jul 2015
Regeneron and Sanofi Announce FDA Approval of Praluent(R) (alirocumab) Injection, the First PCSK9 Inhibitor in the U.S., for the Treatment of High LDL Cholesterol in Adult Patients
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 24 Jul 2015
Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent(R) (alirocumab) for the Treatment of Hypercholesterolemia
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 20 Jan 2014
Aegerion Pharmaceuticals' JUXTAPID(R) (lomitapide) Capsules Approved in Mexico for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 7 Feb 2013
Amgen Outlines Long-Term Strategy
Biopharmaceuticals
 HSMN NewsFeed - 25 Oct 2011
Aegerion Pharmaceuticals Appoints Craig E. Fraser as President, U.S.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Jul 2011
Genzyme and Isis Announce Submission of European Marketing Authorization Application for Mipomersen (Kynamro(R))
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 21 Jul 2011
Aegerion Pharmaceuticals Announces Appointment of Paul G. Thomas to Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Feb 2011
Aegerion Pharmaceuticals Appoints Diane L. Tribble, Ph.D., M.M.Sc., as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Feb 2011
Aegerion Pharmaceuticals Appoints Martha J. Carter as Chief Regulatory Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Aug 2010
Impax Laboratories Confirms Patent Challenge Relating to VYTORIN(R), 10 mg/80 mg
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 23 Dec 2009
Lilly, Kowa and Kowa Pharmaceuticals America Announce Co-Promotion and Licensing Agreement
Biopharmaceuticals Cardiology Licensing
 HSMN NewsFeed - 5 Aug 2009
Merck and Schering-Plough Resolve Previously Disclosed Civil Class Action Lawsuits Related to VYTORIN(R) (ezetimibe/simvastatin) and ZETIA(R) (ezetimibe)
Biopharmaceuticals Cardiology Litigation
 HSMN NewsFeed - 20 May 2009
Genzyme and Isis Announce that Mipomersen Phase 3 Study in Patients with Homozygous Familial Hypercholesterolemia Met Primary Endpoint
Biopharmaceuticals
 HSMN NewsFeed - 30 Jan 2009
Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash
Diagnostics Mergers & Acquisitions
 HSMN NewsFeed - 24 Jun 2008
Genzyme and Isis Complete Licensing of Mipomersen
Biopharmaceuticals Licensing
 HSMN NewsFeed - 25 Apr 2008
FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen
Biopharmaceuticals FDA
 HSMN NewsFeed - 31 Mar 2008
Update on ACHIEVE: A Study of Merck's Investigational Extended-Release Niacin/Laropiprant (CORDAPTIVE(TM))
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 25 Jan 2008
Merck and Schering-Plough Respond To Issues Raised About ENHANCE Clinical Trial
Biopharmaceuticals
 HSMN NewsFeed - 14 Jan 2008
Merck/Schering-Plough Pharmaceuticals Provides Results of the ENHANCE Trial
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 7 Jan 2008
Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
Biopharmaceuticals Cardiology Licensing
 HSMN NewsFeed - 20 Nov 2007
Merck/Schering-Plough Pharmaceuticals Provides Update on ENHANCE Trial
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 23 Oct 2007
Genzyme Launches Cholestagel(R) in Europe
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 8 Jun 2007
Schering-Plough and Bayer Healthcare Announce Availability of ZETIA in Japan, the First Cholesterol-Lowering Agent With a Novel Mechanism of Action Approved in Japan in 18 Years
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 17 May 2007
Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS 301012 in Familial Hypercholesterolemia Patients
Biopharmaceuticals
 HSMN NewsFeed - 9 May 2007
New AHA Guidelines Increase the Number of Children and Adolescents Recommended for Cholesterol Screening
Diagnostics Cardiology
 HSMN NewsFeed - 18 Apr 2007
Schering-Plough Announces ZETIA Approved in Japan for Treatment of High Cholesterol
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 26 Mar 2007
Two New Imaging Studies Show Higher Dose Lipitor Stopped the Progression of Atherosclerosis
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 26 Mar 2007
Merck and Schering-Plough to Develop Another New Cholesterol Lowering Medicine
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 10 Jan 2007
New England Journal of Medicine Reports Aegerion's Lead Compound Reduces LDL By 51% in Patients With a Severe Form of Hypercholesterolemia
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 21 Dec 2006
Data Recently Published in Mayo Clinic Proceedings Showed VYTORIN(R) (ezetimibe/simvastatin) Superior to Lipitor (atorvastatin) in Reducing LDL ''Bad'' Cholesterol in Patients with Type II Diabetes at the Dose Comparisons Studied
Biopharmaceuticals
 HSMN NewsFeed - 21 Dec 2006
Ranbaxy Granted Final FDA Approval to Market Simvastatin 5, 10, 20 and 40 mg Tablets
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 5 Dec 2006
Alnylam Advances a Systemically Delivered RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia as New Development Program
Biopharmaceuticals
 HSMN NewsFeed - 15 Nov 2006
Merck's Investigational MK-0524 Significantly Reduced Flushing Caused By Extended-Release Niacin in Phase II Study
Biopharmaceuticals
 HSMN NewsFeed - 31 Oct 2006
Pfizer Updates Preliminary Results of Torcetrapib/Atorvastatin Clinical Trials as Abstract for Phase 3 Study is Released
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 5 Oct 2006
FDA Approves New Label for VYTORIN(R) (ezetimibe/simvastatin)
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Jun 2006
Ranbaxy Receives FDA Approval to Market Simvastatin 80mg Tablets with 180-Day Exclusivity
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 1 Jun 2006
Isis Pharmaceuticals Receives Orphan Drug Status for ISIS 301012 for the Treatment of Homozygous Familial Hypercholesterolemia
Biopharmaceuticals FDA
Return to NewsFeed  

 Additional items found! 21

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 21 additional stories matching:
familial hypercholesterolemia
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.